Quantcast

Biotech Initial Public Offerings (IPO's)

For most of us who cannot invest in private companies, access to information about newly formed biotechs is largely restricted until the companies trade their stock publicly and have to file corporate information with the SEC. Therefore, when companies state their intention to "go public" by filing an S-1 (aka prospectus) with the SEC, they provide a new window into their business operations and drug development pipelines. As these companies start trading, this document is the starting place for due diligence research. I'll post documents and links below for companies I have been watching go through this process. Keep in mind that in the past several years, the biotech IPO market has been very challenging, and a number of companies have withdrawn their planned IPOs.

November 2012: The Good, the bad, and the ugly of biotech IPOs (BiotechNow)

Clovis Oncology

  • Click here to download IPO prospectus
  • Company now trades as $CLVS

Hyperion Therapeutics

Merrimack Pharmaceuticals

Puma Biotechnology

Quark Pharmaceuticals

Rib-X Pharmaceuticals

  • Click here to download IPO prospectus
  • The Rib-X lead antibiotic drug candidate utilizes Captisol technology licensed from Ligand $LGND.